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*To the Editor:*

We thank Massart et al for their comments[1](#ajt14909-bib-0001){ref-type="ref"} on our recently published large‐scale genome‐wide association study of renal transplant outcomes,[2](#ajt14909-bib-0002){ref-type="ref"} and we welcome the opportunity to examine their findings in more detail.

The 2 recipient genetic loci highlighted in their paper,[3](#ajt14909-bib-0003){ref-type="ref"} rs10765602 (gene annotation *CCDC67*) and rs7976329 (gene annotation *PTPRO*), were well imputed in our study (INFO\>0.95) and neither reached genome‐wide significance in our reported analyses.[2](#ajt14909-bib-0002){ref-type="ref"} To provide additional confidence, we have reanalyzed our data following reimputation to the 1000 Genomes phase 3 reference panel via the Sanger Imputation Service (www. imputation.sanger.ac.uk) using Eagle and the Positional Burrows‐Wheeler Transform package.[4](#ajt14909-bib-0004){ref-type="ref"}

Table [1](#ajt14909-tbl-0001){ref-type="table"} indicates that neither single nucleotide polymorphism (SNP) reaches a nominal level of statistical significance in either donor or recipient genome for our broader definition of acute rejection (any acute rejection event recorded in the first 12 months after transplantation).

###### 

Results from UKIRTC acute rejection GWAS for rs10765602 and rs7976329

  Test                          rsID         AlleleA   AlleleB   Cases AA   Cases AB   Cases BB   Cases total   ctrls AA   ctrls AB   ctrls BB   ctrls total   MAF cases   MAF controls   *P*    Beta     SE
  ----------------------------- ------------ --------- --------- ---------- ---------- ---------- ------------- ---------- ---------- ---------- ------------- ----------- -------------- ------ -------- -------
  Recipient (null as missing)   rs10765602   G         T         36         152        209        398           73         319        426        818           0.283       0.284          .702   −0.039   0.102
  Recipient (null as missing)   rs7976329    T         C         171        177        50         398           359        359        100        818           0.349       0.342          .636   0.046    0.098
  Recipient (null as control)   rs10765602   G         T         36         152        209        398           146        795        941        1881          0.283       0.289          .676   0.039    0.092
  Recipient (null as control)   rs7976329    T         C         171        177        50         398           805        839        237        1881          0.349       0.349          .823   0.020    0.087
  Donor (null as missing)       rs10765602   G         T         26         160        193        379           49         261        351        661           0.278       0.271          .929   0.010    0.112
  Donor (null as missing)       rs7976329    T         C         150        185        44         379           278        300        83         661           0.361       0.352          .361   0.097    0.106
  Donor (null as control)       rs10765602   G         T         26         160        193        379           117        623        821        1560          0.278       0.274          .922   −0.010   0.100
  Donor (null as control)       rs7976329    T         C         150        185        44         379           656        736        168        1560          0.361       0.343          .323   0.095    0.097

Neither SNP was found to be significantly associated with the acute rejection phenotype in our analysis, in either recipients or donors. The SNPs were imputed to the 1000 Genomes Phase 3 reference panel and analyzed using SNPTEST (frequentist 1, method score). The first 5 principal components, the recruitment site, recipient age, donor age, recipient sex, donor sex, and the total number of HLA mismatches (at A, B, and DR) were included as covariates. Both SNPs, in both recipients and donors, were imputed to a high quality, with an info score and average maximum posterior call of greater than 0.95. Test = recipient/donor to indicate whether recipient or donor genotypes were tested (null as missing /control indicates whether blank records were treated as missing data, or as controls); rsID, SNP identifier; alleleA, noneffect allele (coded as 0); alleleB, effect allele (coded as 1); cases/controls AA, number of case/controls who were homozygous for allele A; cases/controls AB, number of case/controls who heterozygous; cases/controls BB, number of case/controls who were homozygous for allele B; MAF, minor allele frequency (frequency of least common allele in the given dataset); beta, beta coefficient relating to the coded allele (alleleB); SE, standard error of beta coefficient; *P, P‐value*.
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The lack of replication signal in our study, despite greater numbers of cases, may be due to a number of factors. We agree with Massart et al that one reason may be the differences in phenotype definition. Our study was primarily designed and powered to detect genetic variation in donor and recipient genomes associated with long‐term graft survival, as this is the key unmet medical need in clinical renal transplantation outcomes, with currently no effective therapeutic options. Our acute rejection phenotype was established from reported national registry‐based outcomes and was not specific to acute T cell--mediated rejection, and thus signal attenuation may be responsible for the difference. However, we note that in our study the recipient minor allele frequency differences between cases and controls are less than 1%, indicating almost complete attenuation. Alternatively, it is possible that the signals found by Ghisdal et al[3](#ajt14909-bib-0003){ref-type="ref"} are false positives. Even genome‐wide significant signals can be false positives, and as the authors used a pooled‐DNA design, and employed a permutation‐based joint test of association and linkage disequilibrium to determine the significance of hits in their discovery phase, it is difficult to determine the combined (discovery + replication) association p‐values for their SNPs. We believe that further data are needed to resolve this issue.

We agree that genetic variation outside the HLA region is an important consideration in seeking to understand the pathogenesis of long‐term graft survival and potentially identifying novel therapeutic targets to reduce cumulative allograft loss over time. We look forward to working with already established international collaborations[5](#ajt14909-bib-0005){ref-type="ref"} to identify these genetic determinants of long‐term graft survival for the benefit of our patients.
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